Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring
Antineoplastic drugs are hazardous chemical agents used mostly in the treatment of patients with cancer, however health professionals that handle and administer these drugs can become exposed and develop DNA damage. Comet assay is a standard method for assessing DNA damage in human biomonitoring and...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
AIMS Press
2015-09-01
|
Series: | AIMS Molecular Science |
Subjects: | |
Online Access: | http://www.aimspress.com/article/10.3934/genet.2015.3.204 |
_version_ | 1818000171078778880 |
---|---|
author | Carina Ladeira Susana Viegas Mário Pádua Elisabete Carolino Manuel C. Gomes Miguel Brito |
author_facet | Carina Ladeira Susana Viegas Mário Pádua Elisabete Carolino Manuel C. Gomes Miguel Brito |
author_sort | Carina Ladeira |
collection | DOAJ |
description | Antineoplastic drugs are hazardous chemical agents used mostly in the treatment of patients with cancer, however health professionals that handle and administer these drugs can become exposed and develop DNA damage. Comet assay is a standard method for assessing DNA damage in human biomonitoring and, combined with formamidopyrimidine DNA glycosylase (FPG) enzyme, it specifically detects DNA oxidative damage.
The aim of this study was to investigate genotoxic effects in workers occupationally exposed to cytostatics (n = 46), as compared to a control group with no exposure (n = 46) at two Portuguese hospitals, by means of the alkaline comet assay. The potential of the OGG1 Ser326Cys polymorphism as a susceptibility biomarker was also investigated. Exposure was evaluated by investigating the contamination of surfaces and genotoxic assessment was done by alkaline comet assay in peripheral blood lymphocytes. OGG1 Ser326Cys (rs1052133) polymorphism was studied by Real Time PCR.
As for exposure assessment, there were 121 (37%) positive samples out of a total of 327 samples analysed from both hospitals. No statistically significant differences (Mann-Whitney test, p > 0.05) were found between subjects with and without exposure, regarding DNA damage and oxidative DNA damage, nevertheless the exposed group exhibited higher values. Moreover, there was no consistent trend regarding the variation of both biomarkers as assessed by comet assay with OGG1 polymorphism.
Our study was not statistically significant regarding occupational exposure to antineoplastic drugs and genetic damage assessed by comet assay. However, health professionals should be monitored for risk behaviour, in order to ensure that safety measures are applied and protection devices are used correctly. |
first_indexed | 2024-04-14T03:18:38Z |
format | Article |
id | doaj.art-efdc6d830e3940d5b9133f881aa878b3 |
institution | Directory Open Access Journal |
issn | 2372-028X 2372-0301 |
language | English |
last_indexed | 2024-04-14T03:18:38Z |
publishDate | 2015-09-01 |
publisher | AIMS Press |
record_format | Article |
series | AIMS Molecular Science |
spelling | doaj.art-efdc6d830e3940d5b9133f881aa878b32022-12-22T02:15:23ZengAIMS PressAIMS Molecular Science2372-028X2372-03012015-09-0123204218Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoringCarina Ladeira0 Susana Viegas1Mário Pádua2Elisabete Carolino3Manuel C. Gomes4Miguel Brito5Environment and Health Research Group, Escola Superior de Tecnologia da Saúde de Lisboa-IPL, Portugal; Environment and Health Research Group, Escola Superior de Tecnologia da Saúde de Lisboa-IPL, Portugal; Centro de Investigação e Estudos em Saúde Pública, Escola Nacional de Saúde Pública, ENSP, Universidade Nova de Lisboa, Portugal;Environment and Health Research Group, Escola Superior de Tecnologia da Saúde de Lisboa-IPL, PortugalEnvironment and Health Research Group, Escola Superior de Tecnologia da Saúde de Lisboa-IPL, Portugal;Faculdade de Ciências, Universidade de Lisboa, PortugalGrupo de Investigação em Genética e Metabolismo, Escola Superior de Tecnologia da Saúde de Lisboa-IPL, PortugalAntineoplastic drugs are hazardous chemical agents used mostly in the treatment of patients with cancer, however health professionals that handle and administer these drugs can become exposed and develop DNA damage. Comet assay is a standard method for assessing DNA damage in human biomonitoring and, combined with formamidopyrimidine DNA glycosylase (FPG) enzyme, it specifically detects DNA oxidative damage. The aim of this study was to investigate genotoxic effects in workers occupationally exposed to cytostatics (n = 46), as compared to a control group with no exposure (n = 46) at two Portuguese hospitals, by means of the alkaline comet assay. The potential of the OGG1 Ser326Cys polymorphism as a susceptibility biomarker was also investigated. Exposure was evaluated by investigating the contamination of surfaces and genotoxic assessment was done by alkaline comet assay in peripheral blood lymphocytes. OGG1 Ser326Cys (rs1052133) polymorphism was studied by Real Time PCR. As for exposure assessment, there were 121 (37%) positive samples out of a total of 327 samples analysed from both hospitals. No statistically significant differences (Mann-Whitney test, p > 0.05) were found between subjects with and without exposure, regarding DNA damage and oxidative DNA damage, nevertheless the exposed group exhibited higher values. Moreover, there was no consistent trend regarding the variation of both biomarkers as assessed by comet assay with OGG1 polymorphism. Our study was not statistically significant regarding occupational exposure to antineoplastic drugs and genetic damage assessed by comet assay. However, health professionals should be monitored for risk behaviour, in order to ensure that safety measures are applied and protection devices are used correctly.http://www.aimspress.com/article/10.3934/genet.2015.3.204DNA damageComet assayOGG1 polymorphismantineoplastic drugsoccupational exposurebiomonitoring |
spellingShingle | Carina Ladeira Susana Viegas Mário Pádua Elisabete Carolino Manuel C. Gomes Miguel Brito Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring AIMS Molecular Science DNA damage Comet assay OGG1 polymorphism antineoplastic drugs occupational exposure biomonitoring |
title | Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring |
title_full | Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring |
title_fullStr | Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring |
title_full_unstemmed | Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring |
title_short | Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring |
title_sort | relation between dna damage measured by comet assay and ogg1 ser326cys polymorphism in antineoplastic drugs biomonitoring |
topic | DNA damage Comet assay OGG1 polymorphism antineoplastic drugs occupational exposure biomonitoring |
url | http://www.aimspress.com/article/10.3934/genet.2015.3.204 |
work_keys_str_mv | AT carinaladeira relationbetweendnadamagemeasuredbycometassayandogg1ser326cyspolymorphisminantineoplasticdrugsbiomonitoring AT susanaviegas relationbetweendnadamagemeasuredbycometassayandogg1ser326cyspolymorphisminantineoplasticdrugsbiomonitoring AT mariopadua relationbetweendnadamagemeasuredbycometassayandogg1ser326cyspolymorphisminantineoplasticdrugsbiomonitoring AT elisabetecarolino relationbetweendnadamagemeasuredbycometassayandogg1ser326cyspolymorphisminantineoplasticdrugsbiomonitoring AT manuelcgomes relationbetweendnadamagemeasuredbycometassayandogg1ser326cyspolymorphisminantineoplasticdrugsbiomonitoring AT miguelbrito relationbetweendnadamagemeasuredbycometassayandogg1ser326cyspolymorphisminantineoplasticdrugsbiomonitoring |